Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Wave Life Sciences soars on positive DMD trial results
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
$1,000,000 Klick Prize Continues to Showcase Game-Changing AI Ideas for Life Sciences
Klick Health today announced the round two results of its $1,000,000 Klick Prize after awarding a combined $200,000 to four ...
Formula 1 Precision Meets Life Sciences: How IoT Is Accelerating Innovation In Manufacturing
Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...
GlobeSt.com1d
Life Sciences Challenged By Overbuilding
Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...
Chicago Beat: NanoGraf expands footprint, what's next for life sciences in Chicago
The Chicago battery startup announced plans to expand to Flint, Michigan, last week on the heels of a $60 million grant from ...
Hartford Business21h
5 life sciences companies expanding in CT
Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...
GlobalData on MSN1d
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug
The primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.
The Business Journals15h
Activation Capital launches new pre-accelerator for life sciences founders
Richmond’s Activation Capital is launching a pre-accelerator program focused on early-stage founders working in biotech and ...
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his ...
Medicine Buffalo18h
UB CAT announces R&D collaboration awards to eight life sciences companies
Projects focus on cancer therapies, robotic clot removal catheters, and mRNA vaccines, among other technologies ...